NDRA•benzinga•
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $50
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 21, 2025 by benzinga